Nontuberculous Mycobacterial Infection Global Market Report 2024

The global nontuberculous mycobacterial infection market has grown strongly in recent years. It will grow from $13.43 billion in 2023 to $14.25 billion in 2024 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to improved diagnostics, aging population, cystic fibrosis awareness, immunosuppressive medications.

The global nontuberculous mycobacterial infection market is expected to see strong growth in the next few years. It will grow to $18.17 billion in 2028 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to antimicrobial drug development, increasing ntm awareness, advances in genetic research, telehealth and remote monitoring. Major trends in the forecast period include personalized treatment, regulatory focus, combination therapies, digital health tools.

The increasing prevalence of chronic obstructive pulmonary disease (COPD) is set to drive the growth of the nontuberculous mycobacterial infection market in the future. COPD, a chronic respiratory ailment characterized by persistent and often progressive lung airflow limitation, is closely linked to nontuberculous mycobacterial (NTM) infections, resulting in a more pronounced decline in forced expiratory volume in one second (FEV1) and an elevated exacerbation rate. The weakened immune system and lung tissue damage caused by COPD make it more susceptible to NTM bacterial lung infections. For example, as of March 2023, The Scottish Public Health Observatory (ScotPHO), a public health body in Scotland, reported a rise in COPD rates from 2021 to 2022, with male rates increasing from 83.2 to 97.6 per 100,000 individuals, and female rates rising from 72.6 to 97.3. Consequently, the burgeoning prevalence of chronic obstructive pulmonary disease (COPD) propels the nontuberculous mycobacterial infection market's growth.

The growing prevalence of infectious diseases is anticipated to fuel the expansion of the nontuberculous mycobacterial infection market. Infectious diseases, caused by pathogenic microorganisms like bacteria, viruses, fungi, or parasites, can lead to a range of symptoms and health issues and are transmissible from one person to another. The rising occurrence of infectious diseases, including those that can result in Nontuberculous Mycobacterial (NTM) infections, has the potential to stimulate the NTM infection market. This surge can be attributed to increased awareness of these infections, more frequent diagnostic tests and early detection, greater research and development efforts for NTM treatments, and an enhanced demand for therapies addressing NTM pathogens due to the heightened healthcare focus on infectious diseases. For instance, as of December 2022, the United Nations International Children's Emergency Fund (UNICEF) reported pneumonia as the leading infectious disease responsible for the death of over 700,000 children annually, equivalent to approximately 2,000 children per day. Therefore, the mounting prevalence of infectious diseases drives the growth of the nontuberculous mycobacterial infection market.

The nontuberculous mycobacterial infection market faces constraints due to the high treatment costs during the forecast period. The elevated costs of treatment can significantly hinder the management of non-tuberculous mycobacterial (NTM) infections, imposing a financial burden on patients. This burden may lead to delayed or suboptimal treatment, potentially resulting in worsened health outcomes. For instance, in 2023, as reported by the National Library of Medicine, individuals with NTM infection incurred notably higher costs compared to those in the control group. Specifically, for inpatient expenses, the average cost for NTM infection patients was $3934.55, while the control group's average cost stood at $2997.21. In terms of outpatient costs, individuals with NTM infection also experienced higher expenses, with an average cost of $2514.69, while the control group's average outpatient cost was $2115.04. Therefore, the high treatment costs have decelerated the growth of the nontuberculous mycobacterial infection market.

Major companies in the nontuberculous mycobacterial infection market are embracing innovative treatment approval practices to uphold their market position. For instance, in June 2021, Paratek Pharmaceuticals Inc., a US-based pharmaceutical company, received approval to expand the indication for NUZYRA (omadacycline) to include the treatment of community-acquired bacterial pneumonia (CABP) in adults. NUZYRA, a modernized tetracycline designed to overcome tetracycline resistance, exhibits activity across a spectrum of bacteria, including Gram-positive, Gram-negative, atypical, and other drug-resistant strains. Furthermore, in July 2022, the Food and Drug Administration, a US-based federal agency, granted Fast Track designation to NUZYRA for the treatment of nontuberculous mycobacterial (NTM) lung disease due to MAC (Mycobacterium avium complex).

In February 2023, Qurient Co. Ltd., a Korea-based biotech company, entered into a partnership with TB Alliance with the goal of developing telacebec, a drug for the treatment of tuberculosis and other nontuberculous mycobacterial (NTM) infections. The partnership grants TB Alliance the exclusive global license for Telacebec. This signifies that TB Alliance will have the authority to continue its work on the medicine and market it on an international scale. TB Alliance, a South Africa-based non-profit organization, is dedicated to developing and delivering cost-effective TB medications.

Major players in the nontuberculous mycobacterial infection market are Pfizer Inc., Johnson & Johnson, F. Hoffman La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company, Eli Lilly and Company, C.H. Boehringer Sohn AG & Co. KG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma Inc., Vertex Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Horizon Therapeutics PLC, Lupin Limited, BioMarin Pharmaceutical Inc., Ionis Pharmaceuticals Inc., Insmed Incorporated, Paratek Pharmaceuticals Inc., Spero Therapeutics Inc., Aradigm Corporation, Dauntless Pharmaceuticals Inc., Validus Pharmaceuticals LLC.

North America was the largest region in the nontuberculous mycobacterial infection market in 2023. North America is expected to be the fastest-growing region in the forecast period. The regions covered in nontuberculous mycobacterial infection report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the nontuberculous mycobacterial infection market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.

The primary classes of drugs used to treat nontuberculous mycobacterial infections include macrolides, rifampin, aminoglycosides, and others. Macrolides are a class of antibiotics commonly employed in the treatment of various bacterial infections. These drugs can be administered through different routes, including oral, parenteral (injectable), and others, and are distributed through various channels, such as hospital pharmacies, retail pharmacies, and online pharmacies.

This report provides nontuberculous mycobacterial infection market statistics, including nontuberculous mycobacterial infection industry global market size, regional shares, competitors with a nontuberculous mycobacterial infection market share, detailed nontuberculous mycobacterial infection market segments, market trends and opportunities and any further data you may need to thrive in the nontuberculous mycobacterial infection industry. This nontuberculous mycobacterial infection market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The nontuberculous mycobacterial infection market consists of revenues earned by entities by providing services such as treatment planning, antibiotic therapy, monitoring and follow-up. The market value includes the value of related goods sold by the service provider or included within the service offering. The nontuberculous mycobacterial infection market also includes sales of azithromycin, rifampin, ethambutol, streptomycin, medical equipment, pulmonary rehabilitation and supportive care products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.